FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912278786> ?p ?o ?g. }

• W2912278786 endingPage "4845" @default.
• W2912278786 startingPage "4845" @default.
• W2912278786 abstract "Abstract Introduction Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma associated with a poor prognosis. The approval of ibrutinib in November 2013 has changed the treatment paradigm for patients with relapsed or refractory MCL. There remains a lack of information on the current treatment patterns used in clinical practice in a contemporary cohort of commercially insured patients. We aimed to identify the treatment patterns for MCL overall and by line of therapy (LOT) and to describe patient demographics and clinical characteristics in a large cohort of commercially insured MCL patients. Methods A retrospective cohort study was conducted with the IQVIA Real-World Data Adjudicated Claims-US database. Adult patients (≥18 years old) with ≥1 claim for a NCCN-recommended MCL treatment between November 1, 2013 and December 31, 2017 were identified. Index date was the first treatment claim. Patients were also required to have ≥1 diagnosis of MCL during the study period (November 1, 2012 to January 31, 2018), ≥12 months of continuous enrollment prior to index date (pre-index period) and ≥30 days after index date (follow-up period). Patients were excluded if they were ≥65 years at index and not enrolled in Medicare Risk or Medicare Cost, enrolled in a clinical trial during the study period, had evidence of MCL treatment in the pre-index period (except for patients indexed on ibrutinib as it is indicated for MCL patients with ≥1 prior treatment), or had evidence of stem cell transplant (SCT) before index date. The most commonly observed MCL treatment regimens were identified, and demographic and clinical characteristics of patients and treatment durations by regimen were described. Treatment regimen was defined as the combination of all agents observed in the 35-day period after the first MCL treatment claim; treatment duration was defined as the start of treatment until a gap of ≥90 days between end date and next date of treatment or treatment modification. Treatment end date occurred 90 days after the end of the supply for oral medications or 30 days after the last administration for non-oral medications. Results There were 1,785 patients treated with the most commonly observed MCL treatment regimens. The most common regimens, irrespective of LOT, were rituximab monotherapy (including maintenance therapy; n=773, 43.3%), R-CHOP (n=723, 40.5%), B-R (n=436, 24.4%), and ibrutinib monotherapy (n=199, 11.1%). Overall, patients had a median (IQR) age of 57 (52-62) years, and 59.4% were male. Most patients were commercially or self- insured (57.5% and 33.6%, respectively). Patients had a median Charlson Comorbidity Index (CCI) of 0 (IQR 0-1; mean [SD] 0.9 [1.4]), with the most common CCI components being diabetes (15.7%), chronic pulmonary disease (12.8%), and congestive heart failure (9.5%). During the follow-up period (median [IQR] 22.5 [10.5-35.3] months), in addition to the MCL regimen(s), patients received radiation therapy (17.4%), SCT (10.0%), and/or immunotherapy (0.2%). The use of targeted therapies (i.e. lenalidomide, bortezomib) other than ibrutinib was infrequent. When considering treatment lines, R-CHOP was the most commonly observed first regimen, followed by rituximab, B-R, and ibrutinib; for the second and third observed regimens, rituximab was the most common, followed by ibrutinib (Figure 1). The median (IQR) duration for the first observed regimen was 8.1 (3.9-18.0) months for ibrutinib, 5.0 (3.3-5.6) months for B-R, 4.0 (2.5-4.4) months for R-CHOP, and 1.9 (1.7-4.4) months for rituximab; ibrutinib also had the longest duration in the second and third line (median [IQR] 5.5 [2.4-13.5] months and 8.3 [3.9-12.4] months, respectively). Conclusion This is the largest study of MCL patients describing treatment patterns in current clinical practice among commercially insured patients. MCL patients were most commonly treated with chemoimmunotherapy for all treatment lines while ibrutinib was the second most common LOT2 and LOT3 regimen. As the treatment landscape and clinical practice continues to change with the use of novel agents, future studies are warranted to further study toxicities and outcomes in the real-world setting. Disclosures Kabadi: AstraZeneca: Employment. Burudpakdee:IQVIA received funds from AstraZeneca to conduct the analysis, interpret data, and coauthor the publication.: Consultancy. Near:IQVIA received funds from AstraZeneca to conduct the analysis, interpret data, and coauthor the publication.: Consultancy. Wada:IQVIA received funds from AstraZeneca to conduct the analysis, interpret data, and coauthor the publication.: Consultancy. Mato:TG Therapeutics: Research Funding; Sunesis: Honoraria, Research Funding; Acerta: Research Funding; Janssen: Consultancy, Honoraria; AstraZeneca: Consultancy; Pharmacyclics: Consultancy, Honoraria, Research Funding; Regeneron: Research Funding; Celgene: Consultancy; Prime Oncology: Speakers Bureau; Abbvie: Consultancy." @default.
• W2912278786 created "2019-02-21" @default.
• W2912278786 creator A5004446104 @default.
• W2912278786 creator A5022919774 @default.
• W2912278786 creator A5042723532 @default.
• W2912278786 creator A5043779414 @default.
• W2912278786 creator A5058911447 @default.
• W2912278786 creator A5083072418 @default.
• W2912278786 date "2018-11-29" @default.
• W2912278786 modified "2023-10-16" @default.
• W2912278786 title "Real-World Treatment Patterns Among a Contemporary Cohort of Commercially Insured Mantle Cell Lymphoma Patients in the United States" @default.
• W2912278786 doi "https://doi.org/10.1182/blood-2018-99-112532" @default.
• W2912278786 hasPublicationYear "2018" @default.
• W2912278786 type Work @default.
• W2912278786 sameAs 2912278786 @default.
• W2912278786 citedByCount "0" @default.
• W2912278786 crossrefType "journal-article" @default.
• W2912278786 hasAuthorship W2912278786A5004446104 @default.
• W2912278786 hasAuthorship W2912278786A5022919774 @default.
• W2912278786 hasAuthorship W2912278786A5042723532 @default.
• W2912278786 hasAuthorship W2912278786A5043779414 @default.
• W2912278786 hasAuthorship W2912278786A5058911447 @default.
• W2912278786 hasAuthorship W2912278786A5083072418 @default.
• W2912278786 hasBestOaLocation W29122787861 @default.
• W2912278786 hasConcept C126322002 @default.
• W2912278786 hasConcept C167135981 @default.
• W2912278786 hasConcept C187212893 @default.
• W2912278786 hasConcept C2777525834 @default.
• W2912278786 hasConcept C2777938653 @default.
• W2912278786 hasConcept C2778461978 @default.
• W2912278786 hasConcept C2779338263 @default.
• W2912278786 hasConcept C2779878957 @default.
• W2912278786 hasConcept C71924100 @default.
• W2912278786 hasConcept C72563966 @default.
• W2912278786 hasConceptScore W2912278786C126322002 @default.
• W2912278786 hasConceptScore W2912278786C167135981 @default.
• W2912278786 hasConceptScore W2912278786C187212893 @default.
• W2912278786 hasConceptScore W2912278786C2777525834 @default.
• W2912278786 hasConceptScore W2912278786C2777938653 @default.
• W2912278786 hasConceptScore W2912278786C2778461978 @default.
• W2912278786 hasConceptScore W2912278786C2779338263 @default.
• W2912278786 hasConceptScore W2912278786C2779878957 @default.
• W2912278786 hasConceptScore W2912278786C71924100 @default.
• W2912278786 hasConceptScore W2912278786C72563966 @default.
• W2912278786 hasIssue "Supplement 1" @default.
• W2912278786 hasLocation W29122787861 @default.
• W2912278786 hasOpenAccess W2912278786 @default.
• W2912278786 hasPrimaryLocation W29122787861 @default.
• W2912278786 hasRelatedWork W1984972242 @default.
• W2912278786 hasRelatedWork W2133406039 @default.
• W2912278786 hasRelatedWork W2239244313 @default.
• W2912278786 hasRelatedWork W2538734629 @default.
• W2912278786 hasRelatedWork W2741571497 @default.
• W2912278786 hasRelatedWork W2890217044 @default.
• W2912278786 hasRelatedWork W2891566720 @default.
• W2912278786 hasRelatedWork W2980601616 @default.
• W2912278786 hasRelatedWork W3044401996 @default.
• W2912278786 hasRelatedWork W3213883340 @default.
• W2912278786 hasVolume "132" @default.
• W2912278786 isParatext "false" @default.
• W2912278786 isRetracted "false" @default.
• W2912278786 magId "2912278786" @default.
• W2912278786 workType "article" @default.